Table 1 Baseline Data of the harmonic group and electrocautery group
Characteristics | Harmonic | Electrocautery | P value |
|---|---|---|---|
n | 64 | 64 | Â |
Age, mean ± sd | 58.28 ± 11.67 | 56.66 ± 11.50 | 0.429 |
AJCC tumor staging, n (%) | Â | Â | 0.279 |
IA | 32 (50.0%) | 25 (39.1%) | Â |
IB | 0 (0%) | 3 (4.7%) | Â |
IIA | 10 (15.6%) | 17 (26.6%) | Â |
IIB | 12 (18.8%) | 8 (12.5%) | Â |
IIIA | 4 (6.3%) | 5 (7.8%) | Â |
IIIC | 6 (9.4%) | 6 (9.4%) | Â |
Clinical TNM stage, n (%) | Â | Â | 0.777 |
I | 32 (50.0%) | 28 (43.8%) | Â |
II | 22 (34.4%) | 25 (39.1%) | Â |
III | 10 (15.6%) | 11 (17.2%) | Â |
BMI, mean ± sd | 25.63 ± 3.61 | 24.36 ± 3.68 | 0.051 |
Surgery options, n (%) | Â | Â | 0.149 |
Modified radical mastectomy | 52 (81.3%) | 45 (70.3%) | Â |
Breast sparing mastectomy | 12 (18.8%) | 19 (29.7%) | Â |
Comorbidities, n (%) | Â | Â | 0.674 |
DM | 5 (7.8%) | 5 (7.8%) | Â |
HTN | 12 (18.8%) | 7 (10.9%) | Â |
CLD | 2 (3.1%) | 2 (3.1%) | Â |
Histology, n (%) | Â | Â | 0.712 |
Ductal carcinoma | 61 (95.3%) | 60 (93.8%) | Â |
Lobular carcinoma | 2 (3.1%) | 1 (1.6%) | Â |
Other | 1 (1.6%) | 3 (4.7%) | Â |
Family history, n (%) | 1 (1.6%) | 6 (9.4%) | 0.115 |
Parity | 63 (98.4%) | 64 (100%) | >0.05 |
Neoadjuvant therapy, n (%) | 4 (6.3%) | 8 (12.5%) | 0.225 |
Smoking, n (%) | 1 (1.6%) | 5 (7.8%) | 0.208 |
Drinking, n (%) | 3 (4.7%) | 1 (1.6%) | 0.619 |
Extent of lymph node surgery | Â | Â | 0.187 |
SNB | 38 (59.4%) | 34 (53.1%) | Â |
I,II | 15 (23.4%) | 21 (32.8%) | Â |
I,II,III | 11 (17.2%) | 9 (14.1%) | Â |